$226.79
-0.87-0.38%
Últ. Act.: Oct 27, 4:47 PM
Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Alnylam Pharmaceuticals (ALNY) publicó su última previsión de julio 30, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $5.28B - $5.72B para el período.
En comparación con la previsión anterior, Alnylam Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $5.3B - $5.8B.
Alnylam Pharmaceuticals ha emitido 15 actualizaciones de orientación entre el febrero 23, 2023 y el julio 30, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.00 | $1.36 | $1.20 | $1.23 |
| Actual | $1.84 | $1.99 | $1.25 | $2.90 |
| Surprise | -8.00% | +46.3% | +4.17% | +135.8% |
| Revenue | ||||
| Estimate | $1.32B | $1.12B | $1.15B | $992.5M |
| Actual | $1.29B | $1.17B | $1.10B | $1.25B |
| Surprise | -2.02% | +4.26% | -4.64% | +25.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.09 | $2.64 | $2.01 | $2.57 |
| Revenue | ||||
| Consensus | $1.43B | $1.58B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $1.84 | $2.00 | -8.00 % |
| Q1 | Apr 30, 2026 | $1.99 | $1.36 | 46.3 % |
| Q4 | Feb 12, 2026 | $1.25 | $1.20 | 4.17 % |
| Q3 | Oct 30, 2025 | $2.90 | $1.23 | 135.8 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $1.29B | $1.32B | -2.02 % |
| Q1 | Apr 30, 2026 | $1.17B | $1.12B | 4.26 % |
| Q4 | Feb 12, 2026 | $1.10B | $1.15B | -4.64 % |
| Q3 | Oct 30, 2025 | $1.25B | $992.47M | 25.9 % |